Actelion not interested in Basilea
Actelion, the Swiss pharmaceuticals group, is not interested in Swiss rival Basilea, Finanz und Wirtschaft reported. In a wide-ranging interview the Swiss bi-weekly asked Actelion Chief Executive Jean-Paul Clozel if Basilea could be a possible target. Clozel said Basilea has developed exciting medicines but already has a partner. Clozel said he is interested in compounds and not financial opportunities so buying Basilea would not make sense.
Clozel said he is interested in acquiring companies that promise compounds at an early stage of development.
Finanz und Wirtschaft